Dasatinib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
87.97
Gini
0.699
CATDS
0.012
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Dasatinib. Strongest target: ABL2_ARG at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ABL2_ARG | 100.0% | 0.0% |
| 2 | BLK | 100.0% | 0.0% |
| 3 | EPHA3 | 100.0% | 0.0% |
| 4 | EPHA5 | 100.0% | 0.0% |
| 5 | FYN | 100.0% | 0.0% |
| 6 | LCK | 100.0% | 0.0% |
| 7 | YES_YES1 | 100.0% | 0.0% |
| 8 | C_SRC | 100.0% | 0.0% |
| 9 | PEAK1 | 99.9% | 0.1% |
| 10 | HCK | 99.9% | 0.1% |
| 11 | DDR2 | 99.6% | 0.4% |
| 12 | LYN | 99.6% | 0.4% |
| 13 | FRK_PTK5 | 99.5% | 0.5% |
| 14 | EPHA2 | 99.4% | 0.6% |
| 15 | EPHB1 | 99.4% | 0.6% |
| 16 | DDR1 | 99.3% | 0.7% |
| 17 | BTK | 99.3% | 0.7% |
| 18 | EPHB4 | 99.3% | 0.7% |
| 19 | TXK | 99.1% | 0.9% |
| 20 | EPHA1 | 98.9% | 1.1% |
Selectivity landscape
Where Dasatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Dasatinib.
Atlas insights for Dasatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 3030.69 | |
| ALLOGRAFT_REJECTION | 10882.35 | |
| ANDROGEN_RESPONSE | 2018.74 | |
| ANGIOGENESIS | 1997.74 | |
| APICAL_JUNCTION | 11616.36 | |
| APICAL_SURFACE | 1261.56 | |
| APOPTOSIS | 8060.76 | |
| BILE_ACID_METABOLISM | 1172.32 | |
| CHOLESTEROL_HOMEOSTASIS | 1811.97 | |
| COAGULATION | 1464.31 | |
| COMPLEMENT | 7156.86 | |
| DNA_REPAIR | 2135.65 | |
| E2F_TARGETS | 4482.05 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2130.15 | |
| ESTROGEN_RESPONSE_EARLY | 3655.83 | |
| ESTROGEN_RESPONSE_LATE | 3166.68 | |
| FATTY_ACID_METABOLISM | 983.50 | |
| G2M_CHECKPOINT | 4593.56 | |
| GLYCOLYSIS | 2757.24 | |
| HEDGEHOG_SIGNALING | 1286.09 | |
| HEME_METABOLISM | 2255.91 | |
| HYPOXIA | 4854.71 | |
| IL2_STAT5_SIGNALING | 4003.50 | |
| IL6_JAK_STAT3_SIGNALING | 5775.42 | |
| INFLAMMATORY_RESPONSE | 6066.25 | |
| INTERFERON_ALPHA_RESPONSE | 1094.21 | |
| INTERFERON_GAMMA_RESPONSE | 6940.43 | |
| KRAS_SIGNALING_DN | 1075.47 | |
| KRAS_SIGNALING_UP | 4394.76 | |
| MITOTIC_SPINDLE | 7475.08 | |
| MTORC1_SIGNALING | 4056.77 | |
| MYC_TARGETS_V1 | 3270.53 | |
| MYC_TARGETS_V2 | 637.98 | |
| MYOGENESIS | 3538.14 | |
| NOTCH_SIGNALING | 392.10 | |
| OXIDATIVE_PHOSPHORYLATION | 1419.05 | |
| P53_PATHWAY | 4236.36 | |
| PANCREAS_BETA_CELLS | 267.37 | |
| PEROXISOME | 1007.77 | |
| PI3K_AKT_MTOR_SIGNALING | 10732.42 | |
| PROTEIN_SECRETION | 2294.07 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 684.08 | |
| SPERMATOGENESIS | 1564.73 | |
| TGF_BETA_SIGNALING | 2090.79 | |
| TNFA_SIGNALING_VIA_NFKB | 4988.35 | |
| UNFOLDED_PROTEIN_RESPONSE | 1223.03 | |
| UV_RESPONSE_DN | 5885.73 | |
| UV_RESPONSE_UP | 4481.78 | |
| WNT_BETA_CATENIN_SIGNALING | 2292.97 | |
| XENOBIOTIC_METABOLISM | 2237.16 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.829 |
| EPT0291 | EPN | 0.826 |
| SRR10899984 | — | 0.815 |
| aMVAC.P_005_TURBT_S223 | — | 0.812 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.810 |
Annotations
Sign in to read and post annotations.
Loading…